Canon Inc.: From Tokyo Optics Workshop to One of Three Global Lithography Platforms

TYO:7751

Few Japanese companies span as many strategic technology frontiers as Canon. Founded in 1937 as a precision optics workshop, it is today a ¥4.5 trillion group straddling consumer imaging, office multifunction printers, medical systems, and — most quietly but most consequentially — semiconductor lithography equipment. This report traces how Canon turned a 35mm rangefinder startup into one of the very few companies on earth with a credible answer to ASML, and what global partners should understand about its next decade.

Snapshot

The Four-Pillar Portfolio

Canon reorganised its reporting structure in recent years around four business groups. The balance between them tells the strategic story better than any slogan.

1. Printing (approx. 45% of sales)

Office multifunction printers under the imageRUNNER and imagePRESS brands, plus the production print business from the 2010 acquisition of Océ, make Canon the world’s largest office imaging franchise by unit share. This is the cash engine: high-margin consumables, deep channel relationships, and recurring service contracts. It funds the other pillars.

2. Imaging (approx. 20% of sales)

The historic heart of the company — EOS cameras, Cine EOS cinema lenses, and the broadcast lens business. After the global DSLR market collapsed from 120 million units in 2010 to under 8 million today, Canon bet everything on mirrorless with the EOS R system in 2018. FY2024 showed the payoff: interchangeable-lens camera unit sales rose for the third consecutive year, and Canon reclaimed the global No. 1 share in mirrorless by value.

3. Medical (approx. 12% of sales)

Canon Medical Systems — acquired from Toshiba in 2016 for ¥665.5 billion — gave Canon an instant foothold in CT, MRI, ultrasound, and X-ray. The 2024 launch of Aquilion ONE / INSIGHT Edition, a deep-learning-powered CT scanner, is the most visible proof that Canon is integrating its imaging AI heritage into clinical hardware. Target: ¥1 trillion medical revenue by 2030.

4. Industrial & Others (approx. 23% of sales)

This is where the most interesting bet sits: semiconductor lithography.

The Nanoimprint Bet: Canon’s Quiet Challenge to ASML

In October 2023, Canon launched the FPA-1200NZ2C, a nanoimprint lithography (NIL) system capable of a minimum linewidth of 14 nanometres — with a roadmap to 10 nm and below. For context, this is the first credible non-EUV path to advanced-node chipmaking, and it targets a market that ASML effectively monopolises with machines that cost more than US$200 million each.

Nanoimprint works by stamping a mask pattern directly onto resist, rather than projecting it through complex optics. The advantages Canon emphasises:

• Approximately 1/10th the power consumption of an EUV tool
• Meaningfully lower system cost
• Simpler optical path, no light source complexity

The trade-offs are equally real: throughput, defect density, and mask lifetime remain areas where EUV is mature and NIL is proving itself. Canon’s early customers include SK hynix for DRAM development and Texas Instruments for specialty logic. The strategic question for 2026-2030 is not whether Canon replaces ASML — it will not — but whether nanoimprint captures a meaningful slice of DRAM and 3D NAND production, where its economics look strongest.

Financial Trajectory

The five-year recovery from the pandemic trough is steady rather than spectacular — but it is accompanied by a decisive rotation of earnings mix. Cameras and printers, once 80% of profit, are now closer to 60%. Medical and industrial together contribute the fastest-growing share of operating profit.

Global Footprint

• Americas: approx. 28% of revenue; Canon USA (Melville, NY) anchors consumer imaging and office solutions
• Europe: approx. 24% of revenue; production print strength from the Océ heritage
• Asia & Oceania (ex-Japan): approx. 26% of revenue; manufacturing footprint across Vietnam, Thailand, Taiwan, the Philippines
• Japan: approx. 22% of revenue

Canon was one of the first major Japanese electronics companies to invest seriously in Southeast Asian production (Vietnam since 2001), which today insulates it from the yen volatility that punishes peers still heavily export-exposed from Japan.

What International Partners Should Watch

1. Medical expansion through AI

Canon’s deep-learning reconstruction software AiCE is now embedded across CT and MRI. Hospital buyers evaluating Canon versus GE and Siemens Healthineers should assume the hardware is competitive and that the differentiator is increasingly the image-processing AI stack. Reimbursement bodies in Europe and the US have begun including AiCE-reconstructed studies in approved protocols.

2. The nanoimprint supply chain

If NIL gains DRAM traction, mask blank suppliers, resist chemistry firms, and equipment service partners will be the indirect winners. Canon’s NIL ecosystem is deliberately Japan-centric (Dai Nippon Printing and Toppan supply master templates) — opportunities exist for non-Japanese specialty-chemicals players willing to qualify into the stack.

3. Production print consolidation

The global production printing market is slowly consolidating around three vendors: Canon (with Océ), Fujifilm (after acquiring Xerox’s share of Fuji Xerox), and Ricoh. Large enterprise procurement leaders should expect pricing discipline rather than discounting over the next cycle.

4. IP and licensing

Canon is consistently in the global top 5 for US patent grants (3,473 in 2023). Its optical and imaging portfolios are licensed into smartphones, security cameras, and automotive ADAS systems. Licensing inquiries — historically difficult to open — have been easier since Canon spun up a dedicated IP monetisation unit in 2022.

Risks and Counterweights

• Office printing secular decline: paper-print volumes are falling 3-5% a year in developed markets. Canon’s mitigation is production print and services, but the cash engine is aging.
• Nanoimprint execution risk: the technology remains unproven at volume. A stumble here would not sink Canon, but it would close a rare window for Japanese semiconductor equipment to reclaim leadership lost to ASML in the 2000s.
• Medical integration: eight years after the Toshiba Medical acquisition, margins still trail Siemens Healthineers. Canon needs to prove the AI-driven differentiation translates to pricing power.
• Succession: Chairman & CEO Fujio Mitarai is 90 years old. His succession is the single most-watched governance question in Japanese corporate circles.

The Long Arc

Canon is not a company that moves fast. It moved slowly into mirrorless and almost lost the camera market. It moved slowly into medical and is still catching up. But when Canon commits, it commits on 20-year timeframes — the nanoimprint R&D programme began in the mid-2000s, and the Océ integration took nearly a decade to bear fruit.

For international partners, the practical posture is straightforward: engage early in medical AI and NIL ecosystem projects, where Canon is actively seeking co-development; treat the printing business as a mature procurement category; and watch the CEO succession, because the answer will shape Canon’s risk appetite for the 2030s.

The company that began by copying Leica in a small Tokyo workshop now owns one of only three credible semiconductor lithography platforms in existence. That sentence would have been unthinkable twenty years ago. It is the central fact about Canon today.